
Steve Lacroix
Chercheur universitaire
Axe Neurosciences
Neuro-inflammation
Neuroscience cellulaire
Neurodégénérescence
Immunité innée
Auto-immunité
Étude des cellules gliales
Thérapie génique et moléculaire
Publications
View all-
article Hammond BP, Zia S, Hahn E, Kapustina M, Lange T, Friesen S, Manek R, Lee KV, Castellanos-Molina A, Bretheau F, Cembrowski MS, Kerr BJ, Lacroix S, Plemel JR
CSF-1R ligands promote microglial proliferation but are not the sole regulators of developmental microglial proliferation
Development 2025.
-
article Castellanos-Molina A, Bretheau F, Boisvert A, Bélanger D, Lacroix S
Constitutive DAMPs in CNS injury: From preclinical insights to clinical perspectives
Brain Behav Immun 122 2024.
-
article Dauchez A, Hankard A, Lacroix S
[Interleukin-1 neuronal receptor induces pain in chronic inflammatory diseases]
Med Sci (Paris) 37 (8-9), 2021.
Projects
- Role of inflammation in recovery after spinal cord injury, from 2021-04-01 to 2026-03-01
- Untangling secondary degeneration and pain from inflammation after spinal cord injury, from 2024-07-01 to 2026-06-30
- Identifying the role of proinflammatory cytokines in pain in multiple sclerosis, from 2025-04-01 to 2028-03-31
- Identifying the role of inflammatory cytokines in pain after nervous system injury., from 2025-04-01 to 2030-03-31
- Manipulating the neuroimmune response to promote spinal cord repair, from 2019-04-01 to 2024-03-31
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
- Elucidating the role of the IL-1 system in the pathogenesis of CNS autoimmunity, from 2020-04-01 to 2025-03-31
- Interleukin-1 alpha mediates secondary degeneration and neuropathic pain after spinal cord injury, from 2020-04-01 to 2023-06-30
- Thérapie génique ciblée dans un modèle de sclérose en plaques, from 2021-05-01 to 2024-04-30
- The identification of the molecular mechanisms through which neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases , from 2023-04-17 to 2024-03-31